Total Value in 2020: $20.06M (74 deals)

Deal title Principal company/nonprofit Partner company/nonprofit Value (US$M) Start date


Advent to manufacture Jenner Institute's ChAdOx1 nCoV-19 vaccine against coronavirus infection Advent Srl The Jenner Institute Payment unspecified 2/10/20
Sapphire Biotech and ASU to conduct preclinical studies using quiescin sulfhydryl oxidase 1 as anti-neoplastic compounds Arizona State University Sapphire Biotech Inc. Payment unspecified 2/10/20
Biomarin and ARUP laboratories to develop companion diagnostic for valoctocogene roxaparvovec in hemophilia A patients ARUP Laboratories Biomarin Pharmaceutical Inc. Payment unspecified 2/20/20
Children's Memorial Health Institute to conduct phase I clinical trial of CNS Pharma's Berubicin against pediatric brain cancer in Poland Children's Memorial Health Institute, Poland CNS Pharmaceuticals Inc. Payment unspecified 2/11/20
Chugai to supply cancer drugs to National Cancer Center Japan for patient-requested therapy system Chugai Pharmaceutical Co. Ltd. Japanese National Cancer Center Payment unspecified 2/7/20
University of Rochester and Evgen to advance SFX-01 into a clinical trial against chronic kidney disease Evgen Pharma plc University of Rochester Payment unspecified 2/13/20
German Red Cross to supply Erytech's donor red blood cells to manufacture eryaspase in Europe German Red Cross Blood Donor Service Erytech Pharma SA Payment unspecified 2/20/20
Oncologie and Moffitt Cancer Center to study tumor microenvironment for precision medicine against gastric and gastrointestinal cancers H Lee Moffitt Cancer Center and Research Institute Oncologie Inc. Payment unspecified 2/25/20
BARDA and Janssen to develop coronavirus vaccine against COVID-19 coronavirus Johnson & Johnson U.S. Department of Health and Human Services Payment unspecified 2/11/20
Cocrystal to use intellectual property rights related to KSURF's antiviral compounds for the treatment of norovirus and coronavirus infections Kansas State University Research Foundation Cocrystal Pharma Inc. $3.20 2/12/20
Bridge Biotherapeutics acquires Konkuk University's drug development candidate for back-eye disorder treatments Konkuk University Bridge Biotherapeutics Inc. $8.53 2/5/20
LDC and Leibniz Institute to develop GRK-5 Inhibitors for the treatment of heart failure and cardiac hypertrophy Leibniz - Institut Für Analytische Wissenschaften - Isas - Ev Lead Discovery Center GmbH Payment unspecified 2/5/20
Theratechnologies and Massachusetts General Hospital for the development of tesamorelin against nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in people living with HIV Massachusetts General Hospital Theratechnologies Inc. Payment unspecified 2/4/20
INIA and AB-Biotics to develop and commercialize probiotic strains as antimicrobials worldwide National Institute of Agricultural and Food Technology and Research (INIA) AB Biotics Payment unspecified 2/10/20
Novartis and DNDi to develop oral LXE-408 for visceral leishmaniasis Novartis AG Drugs for Neglected Diseases Initiative Payment unspecified 2/25/20
Orgenesis to provide point-of-care platform for John Hopkins University to develop and supply cell and gene based clinical therapeutics Orgenesis Inc. Johns Hopkins University Payment unspecified 2/19/20
Toa Eiyo to develop Osaka University's CNT-01 against triglyceride deposit cardiomyovasculopathy worldwide Osaka University Toa Eiyo KK Payment unspecified 2/17/20
Gibson Oncology to commercialize Purdue University's Azaindenoisoquinolines against cancer worldwide Purdue University Gibson Oncology LLC Payment unspecified 2/10/20
RFU and Exicure to develop therapeutics for genetic diseases Rosalind Franklin University of Medicine & Science Exicure Inc. Payment unspecified 2/13/20
BARDA and Sanofi to develop coronavirus vaccine candidate using recombinant DNA platform for Coronavirus infection Sanofi Pasteur Inc. U.S. Department of Health and Human Services Payment unspecified 2/18/20
Enochian Biosciences acquires hepatitis B virus therapy from Seraph Research Institute Seraph Research Institute Enochian Biosciences Inc. Payment unspecified 2/2/20
Cystic Fibrosis Foundation to support the development of Synspira Therapeutics' SNSP-003 to treat malabsorption syndromes Synspira Therapeutics Inc. Cystic Fibrosis Foundation Payment unspecified 2/12/20
Beroni and Tianjin University to develop a medical solution for the Covid-19 infection Tianjin University Beroni Group Ltd. Payment unspecified 2/20/20
TMDU and ACT Genomics to evaluate genomic profiles in Japanese cancer patients Tokyo Medical and Dental University ACT Genomics Co. Ltd. Payment unspecified 2/12/20
Sanofi Pasteur and HHS to advance COVID-19 vaccine U.S. Department of Health and Human Services Sanofi Pasteur Inc. Payment unspecified 2/18/20
University of Campinas and Entourage to identify and develop therapeutic candidates from 240 cannabis varieties for refractory epilepsy Universidade Estadual de Campina Entourage Phytolab Payment unspecified 2/3/20
University of Alaska Fairbanks to grant rights of drug composition patent to Be Cool Pharmaceutics for inducing hibernation state University of Alaska Fairbanks Be Cool Pharmaceutics LLC Payment unspecified 2/3/20
UCI and Agex to develop and commercialize cell therapies using Purestem technology for neurological disorders University of California Irvine Agex Therapeutics Inc. Payment unspecified 2/3/20
Benevolentai and University of California to discover and develop non-invasive therapeutic treatments for cerebral cavernous malformations University of California San Diego Benevolentai Ltd. Payment unspecified 2/12/20
Genprex to use University of Pittsburgh's gene therapy candidate for the treatment of type 1 and type 2 diabetes University of Pittsburgh Genprex Inc. Payment unspecified 2/11/20
GSK and University of Queensland to develop 2019-nCoV vaccine using pandemic vaccine adjuvant platform technology University of Queensland Glaxosmithkline plc Payment unspecified 2/3/20
NCI to enter a CRADA with VBL Therapeutics to evaluate VB-111 in combination in phase II study with nivolumab in patients with metastatic colorectal cancer VBL Therapeutics National Cancer Institute Payment unspecified 2/20/20
WPD Pharmaceuticals to use Wake Forest University's intellectual property rights related to WPD-101, WPD-102 and WPD-103 for glioblastoma and other tumors Wake Forest University WPD Pharmaceuticals Inc. Payment unspecified 2/24/20
Dianomi Therapeutics licensed a second suite of intellectual property from the Wisconsin Alumni Research Foundation to expand use of mineral-coated microparticle technology into nucleic acid therapy Wisconsin Alumni Research Foundation Dianomi Therapeutics Inc. Payment unspecified 2/11/20

No Comments